Challenges in Forecasting Antimicrobial Resistance.

Blumberg S Cascante Vega J Medford RJ Robin T Suggested citation for this article: Pei S Zhang Y antimicrobial resistance et al. Challenges in forecasting antimicrobial resistance. Emerg Infect Dis. 2023 Apr [date cited]. https://doi.org/10.3201/eid2904.221552 healthcare-associated infections infectious disease forecasting

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
04 2023
Historique:
entrez: 23 3 2023
pubmed: 24 3 2023
medline: 28 3 2023
Statut: ppublish

Résumé

Antimicrobial resistance is a major threat to human health. Since the 2000s, computational tools for predicting infectious diseases have been greatly advanced; however, efforts to develop real-time forecasting models for antimicrobial-resistant organisms (AMROs) have been absent. In this perspective, we discuss the utility of AMRO forecasting at different scales, highlight the challenges in this field, and suggest future research priorities. We also discuss challenges in scientific understanding, access to high-quality data, model calibration, and implementation and evaluation of forecasting models. We further highlight the need to initiate research on AMRO forecasting using currently available data and resources to galvanize the research community and address initial practical questions.

Identifiants

pubmed: 36958029
doi: 10.3201/eid2904.221552
pmc: PMC10045679
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

679-685

Subventions

Organisme : NCEZID CDC HHS
ID : U01 CK000538
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000594
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000592
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000531
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000590
Pays : United States

Références

J R Soc Interface. 2010 Jun 6;7(47):905-19
pubmed: 19940002
Curr Opin Infect Dis. 2011 Jun;24(3):279-87
pubmed: 21467930
Elife. 2018 Dec 18;7:
pubmed: 30560781
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24268-24274
pubmed: 31712420
Antimicrob Resist Infect Control. 2021 Mar 31;10(1):63
pubmed: 33789754
PLoS Comput Biol. 2021 Jan 14;17(1):e1008417
pubmed: 33444378
BMC Infect Dis. 2019 Nov 29;19(1):1011
pubmed: 31783803
Science. 2000 Jan 28;287(5453):650-4
pubmed: 10649998
Trends Microbiol. 2019 Oct;27(10):864-877
pubmed: 31288975
Arch Surg. 1998 Dec;133(12):1343-6
pubmed: 9865653
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3153-8
pubmed: 15677330
Math Med Biol. 2015 Mar;32(1):79-98
pubmed: 24114068
BMC Med. 2019 Apr 24;17(1):81
pubmed: 31014341
Sci Rep. 2019 Jan 24;9(1):683
pubmed: 30679458
Evol Appl. 2019 Jan 21;12(3):365-383
pubmed: 30828361
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11988-E11995
pubmed: 30559213
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1075-1080
pubmed: 28096340
MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):826-31
pubmed: 26247436
J R Soc Interface. 2018 Jun;15(143):
pubmed: 29925579
Infect Control Hosp Epidemiol. 2014 Dec;35(12):1521-30
pubmed: 25419775
J Infect Dis. 2021 Jun 16;223(12 Suppl 2):S209-S213
pubmed: 33326581
Infect Control Hosp Epidemiol. 2011 Jun;32(6):562-72
pubmed: 21558768
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Front Microbiol. 2013 Apr 17;4:87
pubmed: 23616784
BMC Infect Dis. 2016 Jul 22;16:357
pubmed: 27449080
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5620-5
pubmed: 16565219
Epidemics. 2018 Sep;24:26-33
pubmed: 29506911
Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):
pubmed: 34493678
Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3146-3154
pubmed: 30647115
PLoS Pathog. 2019 May 13;15(5):e1007763
pubmed: 31083687
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29063-29068
pubmed: 33139558
Clin Infect Dis. 2020 Jan 16;70(3):388-394
pubmed: 30919885
Am J Epidemiol. 2013 Jun 1;177(11):1306-13
pubmed: 23592544
PLoS One. 2019 Jun 10;14(6):e0218134
pubmed: 31181106
Lancet Infect Dis. 2015 Dec;15(12):1438-49
pubmed: 26411518
Clin Infect Dis. 2001 Nov 15;33(10):1739-46
pubmed: 11595995
Elife. 2018 Dec 18;7:
pubmed: 30560786
Science. 1996 Jul 26;273(5274):497-500
pubmed: 8662538
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2113561119
pubmed: 35394862
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10223-8
pubmed: 15220470
Epidemics. 2018 Mar;22:13-21
pubmed: 28958414
Clin Infect Dis. 2017 Aug 15;65(4):581-587
pubmed: 28472233
Nat Ecol Evol. 2019 Mar;3(3):440-449
pubmed: 30742105
Am J Epidemiol. 2008 Sep 1;168(5):548-57
pubmed: 18635575
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12902-12910
pubmed: 30559176
Nat Microbiol. 2019 Jul;4(7):1160-1172
pubmed: 30962570

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH